The future of the global transdermal skin patch market looks promising with opportunities in the pain relief, smoking reduction and cessation aid, overactive bladder, and hormonal therapy markets. The global transdermal skin patch market is expected to reach an estimated $9.7 billion by 2030 with a CAGR of 4.7% from 2024 to 2030. The major drivers for this market are growing benefits over oral and ingested drugs, convenience of use, and extended duration of the drug's action, as well as, increasing funding and investments for drug development.

Some of the Key Questions answered in this exclusive report are:

Q.1. What are some of the most promising, high-growth opportunities for the transdermal skin patch market by type (single-layer drug-in-adhesive, multi-layer drug-in-adhesive, matrix, and others), application (pain relief, smoking reduction and cessation aid, overactive bladder, hormonal therapy, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?

Q.2. Which segments will grow at a faster pace and why?

Q.3.  Which region will grow at a faster pace and why?

Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?

Q.5. What are the business risks and competitive threats in this market?

Q.6.  What are the emerging trends in this market and the reasons behind them?

Q.7. What are some of the changing demands of customers in the market?

Q.8. What are the new developments in the market? Which companies are leading these developments?

Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?

Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?

Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Market Segmentation:

In this market, single-layer drug-in-adhesive, multi-layer drug-in-adhesive, and matrix are the major segments of transdermal skin patch market by type. Lucintel forecasts that single-layer drug-in-adhesive is expected to witness the highest growth over the forecast period.

Within this market, pain relief is expected to witness the higher growth due to increasing prevalence of pain-related disorders, such as diabetic neuropathy, rheumatoid arthritis, osteoarthritis, migraine, and other.

North America will remain the largest region over the forecast period due to the presence of key stakeholders and a well-established health care system in the region.

Teva Pharmaceutical Industries, Novartis, Teikoku Pharma, Viatris, Johnson & Johnson, Luye Pharma Group, and Purdue Pharma Manufacturing are the major suppliers in the transdermal skin patch market